Pre-workout Supplement Versus Caffeine on Energy Expenditure.

Northern Illinois University

Status: Completed

Conditions: Healthy

Treatments: Dietary Supplement: Crystal Light; Dietary Supplement: ENGN Shred; Dietary Supplement: Nutricost caffeine powder

Study type: Interventional

Funder types: Other

Identifiers

NCT04539054

HS19-0163

Details and patient eligibility

About

The primary purpose of this study was to examine the acute effects of a multi-ingredient pre-workout supplement versus an ergogenic dose of caffeine (6 mg/kg) on energy expenditure during low-intensity exercise. The effects of these substances on substrate utilization, gas exchange, and psychological factors were also investigated. Twelve males (mean ± SD: age = 22.8 ± 2.4 years) completed three bouts of 60-min of treadmill exercise at 4.8-6.4 km/hr on separate days after consuming a pre-workout supplement, 6 mg/kg of caffeine, or placebo in a randomized fashion. The pre-workout and caffeine supplements resulted in significantly greater energy expenditure (p < 0.001, p = 0.006, respectively), VO2 (p < 0.001, p = 0.007, respectively), VCO2 (p = 0.006, p = 0.049, respectively), and VE (p < 0.001, p = 0.007, respectively), but not rates of fat or carbohydrate oxidation or respiratory exchange ratio compared to placebo (collapsed across condition). In addition, the pre-workout supplement increased feelings of alertness (p = 0.015) and focus (p = 0.005) 30-minutes post-ingestion and decreased feelings of fatigue (p = 0.014) during exercise compared to placebo (collapsed across condition). Thus, the pre-workout supplement increased energy expenditure and measures of gas exchange to the same extent as 6 mg/kg of caffeine with concomitant increased feelings of alertness and focus and decreased feelings of fatigue.

Enrollment: 12 patients

Sex: Male

Ages: 19 to 29 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Male

Exclusion criteria

• history of medical or surgical events, including cardiovascular disease, metabolic, renal, hepatic, or musculoskeletal disorders;
• use of any medications
• use of nutritional supplements
• habitual use of caffeine (≥1 caffeinated beverage per day)
• participation in another clinical trial or investigation of another investigational product within 30 days prior to screening/enrollment.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

12 participants in 3 patient groups, including a placebo group

Pre-Workout Condition

Experimental group

Description:

This condition consisted of the ingestion of one serving of the pre-workout supplement.

Treatment:

Dietary Supplement: ENGN Shred

Caffeine Condition

Experimental group

Description:

This condition consisted of the ingestion of 6 mg of caffeine per kg of body mass.

Treatment:

Dietary Supplement: Nutricost caffeine powder

Placebo condition

Placebo Comparator group

Description:

This condition consisted of the ingestion of a placebo.

Treatment:

Dietary Supplement: Crystal Light